EPIC Act of 2025

Hozzl · 2025-03-27T13:58:00Z

Explore the details of Senate Bill 832 EPIC Act of 2025 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/27/2025, 1:58 PM

Summary of Bill S 832

Bill 119 s 832, also known as the Equalizing Negotiation Periods for Small-Molecule and Biologic Candidates Act, aims to make changes to title XI of the Social Security Act. Specifically, the bill seeks to ensure that the negotiation period for small-molecule and biologic candidates under the Drug Price Negotiation Program is equalized.

Currently, there is a discrepancy in the negotiation periods for small-molecule and biologic candidates, with biologic candidates having a longer negotiation period. This bill aims to address this disparity by equalizing the negotiation period for both types of candidates.

The Drug Price Negotiation Program is a program that allows the government to negotiate drug prices with manufacturers in order to lower costs for consumers. By equalizing the negotiation period for small-molecule and biologic candidates, this bill aims to ensure that both types of drugs are subject to the same negotiation process, ultimately leading to more equitable pricing for consumers. Overall, Bill 119 s 832 seeks to promote fairness and transparency in the drug pricing process by ensuring that all candidates are subject to the same negotiation period under the Drug Price Negotiation Program.

Congressional Summary of S 832

Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 832

Bill S 832 is currently in the status of Bill Introduced since March 4, 2025. Bill S 832 was introduced during Congress 119 and was introduced to the Senate on March 4, 2025. Bill S 832's most recent activity was Read twice and referred to the Committee on Finance. as of March 4, 2025

Bipartisan Support of Bill S 832

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 832

Primary Policy Focus

Health

Alternate Title(s) of Bill S 832

A bill to amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.